Tag Directory / PHARMACEUTICALS     showing 21–40 of 120


Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma / MedCity

Frank Vinluan / medcitynews - Day One Biopharmaceuticals is Servier’s biggest acquisition yet, topping the $2.4 billion it paid to buy Shire’s cancer business in 2018. Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in chi…

#healthcare #pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment #oncology #healthcarefinance

Servier Acquires Day One Biopharmaceuticals for $2.5B, Betting on Tovorafenib and the Pediatric Glioma Frontier

4 days / oncodaily

Agreement with Day One Biopharmaceuticals to Expand Glioma Portfolio – Servier

9 days / oncodaily

Servier: A Caregiver’s Powerful Story on Rare Disease

9 days / oncodaily

Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma

10 days / medcitynews / Frank Vinluan

Servier to buy Day One for $2.5B, gaining rare oncology medicines

10 days / endpoints / Kyle LaHucik

Saturday, March 7, 2026, 12:22 am / permalink 20306 / 5 stories in 9 days


Hospitals urge regulators to halt drugmakers’ expanded 340B data policies / Healthcare Dive

Emily Olsen / healthcaredive - The American Hospital Association argues new policies from Eli Lilly and Novo Nordisk requiring providers to submit more claims data on dispensed 340B drugs is onerous and unlawful.

#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy #hospitaloperations #healthcarefinance

Judge dismisses Pennsylvania hospitals’ lawsuit over CVS’ 340B practices

10 days / beckershospitalreview / Ella Jeffries

Hospitals urge regulators to halt drugmakers’ expanded 340B data policies

11 days / healthcaredive / Emily Olsen

Higher heat stress leads to more cardiac ICU admissions, researchers find

12 days / medicalxpress

Hospitals decry drugmakers' expanded claims reporting policies for 340B

12 days / fiercehealthcare

Friday, March 6, 2026, 12:23 pm / permalink 20277 / 4 stories in 10 days


GLP‑1 drugs may fight addiction across every major substance, according to a study of 600,000 people / Medical Express

medicalxpress - A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He didn't use a patch. He didn't set a quit date. He simply lost interest. It happen…

#obesity #healthcare #pharmaceuticals #elililly #novonordisk #weightloss #publichealth #drugdevelopment #behavioralhealth

GLP-1 receptor agonists linked to lower mortality for patients with brain metastases, T2DM

3 days / medicalxpress

What happens after patients stop GLP-1s?

3 days / beckershospitalreview / Paige Twenter

AAOS: GLP-1 receptor agonist use increases five-year risk for osteoporosis

10 days / medicalxpress

Drugs Behind the Ozempic Weight-Loss Boom May Also Lower the Risk of Addiction

10 days / discovermagazine

Some patients keep weight off with fewer GLP-1 injections, study finds

10 days / medicalxpress

How do GLP-1 agonists affect gene expression?

10 days / medicalxpress

Eric Topol: GLP-1 Drugs Reduce Substance Abuse Risk in Over 600,000 US Veterans

10 days / oncodaily

GLP‑1 drugs may fight addiction across every major substance, according to a study of 600,000 people

11 days / medicalxpress

GLP-1 drugs tied to lower addiction risk: Study

11 days / beckershospitalreview / Ella Jeffries

GLP‑1 drugs like Ozempic may lower the risk of addiction: New study

11 days / medicalxpress

Friday, March 6, 2026, 12:23 pm / permalink 20276 / 10 stories in 10 days


Groundbreaking new drug shows promise for treating children with a devastating form of epilepsy / LiveScience

livescience - An experimental treatment reduces seizures and other symptoms in children with a type of epilepsy called Dravet syndrome.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #infanthealth

Groundbreaking new drug shows promise for treating children with a devastating form of epilepsy

11 days / livescience

Drug breakthrough for children with severe form of epilepsy

12 days / bbc

First gene regulation clinical trials for epilepsy show promising results

12 days / medicalxpress

Life-changing drug identified for children with rare epilepsy

12 days / medicalxpress

Thursday, March 5, 2026, 4:23 pm / permalink 20233 / 4 stories in 11 days


Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less / ESMO

esmo - Findings from the POSEIDON meta-analysis of the MARCAP consortium

#healthcare #pharmaceuticals #publichealth #oncology

Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less

11 days / esmo

Majid Al Othman: POSEIDON Meta-Analysis Results in Post-Prostatectomy Salvage RT

15 days / oncodaily

Sault skiiers bring home medals from youth championships

17 days / sootoday

Thursday, March 5, 2026, 3:23 am / permalink 20175 / 3 stories in 11 days


Novo Nordisk inks $2.1B oral obesity drug deal / Beckers

Ella Jeffries / beckershospitalreview - Novo Nordisk has partnered with Vivtex Corp. to develop next-generation oral biologic medicines for obesity, diabetes and related conditions. Under the agreement, Vivtex will license its proprietary oral drug-delivery technologies to Novo Nordisk and is e…

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #biotech #drugdevelopment #healthcarefinance

Gubra plots Roivant-like model as partnered obesity drugs take flight

3 days / endpoints / Kyle LaHucik

Pfizer gets obesity drug approval in China shortly after buying local rights

10 days / endpoints / Elizabeth Cairns

Trial suggests GLP-1 combo therapy cuts fat while preserving muscle in obesity

11 days / medicalxpress

Roche partner Zealand posts Phase 2 data for amylin obesity drug

11 days / endpoints / Kyle LaHucik

Novo Nordisk details Irish expansion; EuroAPI’s challenges continue

11 days / endpoints / Anna Brown

What to know about how GLP-1 medications might fight addiction

11 days / medicalxpress

Twenty percent of eligible youth prescribed GLP-1 receptor agonists

12 days / medicalxpress

GLP-1 medications get at the heart of addiction, study finds

12 days / medicalxpress

Quitting GLP-1 drugs triggers rapid regain, but 25% of weight loss may last

12 days / medicalxpress

Eli Lilly launches its direct-to-employer platform for obesity drugs

12 days / fiercehealthcare

Most Patients Keep Weight Off With Fewer GLP-1 Shots, Study Finds

12 days / nytimes / Roni Caryn Rabin

AHA urges HHS to block Novo Nordisk’s 340B data demand

12 days / beckershospitalreview / Paige Twenter

FDA sends Novo Nordisk 2nd warning over GLP-1 ads

12 days / beckershospitalreview / Erica Cerutti

How gut bacteria and diet can reprogram fat to burn more energy

12 days / medicalxpress

No more weekly injections? How lettuce cells could deliver GLP-1 pills

12 days / medicalxpress

GLP-1 weight-loss drugs comparably effective across age, race and starting weight

12 days / medicalxpress

FDA ramps up crackdown on GLP-1 drug compounding with fresh batch of 30 warning letters

13 days / fiercehealthcare

FDA warns 30 telehealth firms over compounded GLP-1 claims

13 days / beckershospitalreview / Ella Jeffries

Hims partner Strive Pharmacy will reintroduce GLP-1 pill pulled from market

13 days / endpoints / Shelby Livingston

Novo Nordisk inks $2.1B oral obesity drug deal

14 days / beckershospitalreview / Ella Jeffries

Novo Nordisk Commits Up to $2B to Drug Delivery Startup Vivtex for R&D of Oral Metabolic Meds

19 days / medcitynews / Frank Vinluan

Novo Nordisk teams with Langer-founded biotech for oral obesity drugs

19 days / endpoints / Kyle LaHucik

Tuesday, March 3, 2026, 1:22 am / permalink 20039 / 22 stories in 13 days


Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours / ESMO

esmo - Findings from the PYNNACLE study

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology

Mohamed Emam Sobeih Explores Rezatapopt Activity in TP53 Y220C-Mutated Solid Tumors

3 days / oncodaily

Rezatapopt Shows Early Activity in TP53 Y220C–Mutated Solid Tumors

13 days / oncodaily

Targeting the untargetable cancer—rezatapopt, an oral p53 reactivator

14 days / medicalxpress

Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours

14 days / esmo

Jayastu Senapati: Trial of Rezatapopt in TP53-Y220C Mutated MDS/AML

15 days / oncodaily

Rashid Lui: First-in-Class Oral Selective p53 Reactivator Looks Promising

17 days / oncodaily

Xin Lu on Targeting Mutant p53 in Solid Tumors with Rezatapopt – NEJM Group

17 days / oncodaily

Florent Peyraud: Restoring Function to a Variant of p53 in Solid Tumors

17 days / oncodaily

Aydah AlAwadhi: Targeting the “Undruggable” p53 – A Long Awaited Proof of Principle

17 days / oncodaily

Monday, March 2, 2026, 2:22 am / permalink 19973 / 9 stories in 14 days


Novartis closes Avidity deal as rare heart disease spinout launches / Endpoints

Lei Lei Wu / endpoints - Atrium Therapeutics launched Friday morning as Novartis closed the $12 billion deal to buy Avidity Biosciences and its RNA muscle therapies. The spinout will take on Avidity’s early-stage programs for genetic cardiomyopathies — heart muscle diseases ...

#healthcare #pharmaceuticals #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #healthcarefinance

Atrium Therapeutics Launches With $270M for RNA Therapies Addressing Rare Cardio Conditions

15 days / medcitynews / Frank Vinluan

Novartis closes Avidity deal as rare heart disease spinout launches

17 days / endpoints / Lei Lei Wu

Monday, March 2, 2026, 12:23 am / permalink 19968 / 2 stories in 14 days


Merck Splits Oncology Business Unit as Keytruda Patent Expiry Nears / OncoDaily

oncodaily - On February 23, 2026, Merck announced a reorganization of its Human Health structure into two business units: an Oncology Business Unit and a Specialty, Pharma & Infectious Diseases Business Unit. […]

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #healthcarefinance

Merck KGaA drops two cancer trials on assets from SpringWorks deal

11 days / endpoints / Reynald Castaneda

No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC

13 days / esmo

Cancer Research UK partners with the Royal College of Surgeons of England to help people with rectal cancer avoid unnecessary surgery

13 days / cancerresearchuk / Krishna Sharma

A domain-adaptive deep contrastive network for magnetic resonance imaging-driven bladder cancer classification

14 days / nature

Multicenter ex vivo evaluation of an α-mannosidase–targeted fluorescent probe for intraoperative margin assessment in breast cancer

14 days / nature

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123

14 days / nature

Merck looks to expand Welireg label following combo readouts with Keytruda, Lenvima

16 days / endpoints / Nicole DeFeudis

Merck Splits Oncology Business Unit as Keytruda Patent Expiry Nears

18 days / oncodaily

Merck reorganizes; Blackstone to fund trials for J&J drug

21 days / endpoints / ENDPOINTS

Saturday, February 28, 2026, 3:22 am / permalink 19937 / 9 stories in 16 days


Boehringer wins accelerated approval for first-line use of lung cancer drug / Endpoints

Lei Lei Wu / endpoints - The FDA greenlit an expanded label for Boehringer Ingelheim’s lung cancer drug Hernexeos, marking the first use of the Commissioner's National Priority Voucher for a new indication. Boehringer won an accelerated

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda #oncology

What to know about lung cancer

12 days / medicalxpress

Lurbinectedin in Oncology: Mechanism, Clinical Data, Evolving Role, and Future Directions

14 days / oncodaily

Patrick Soon-Shiong: Anktiva Plus Keytruda Shows Potential to Prolong Survival in Patients with Lung Cancer

15 days / oncodaily

Aakash Desai HER2-Mutant NSCLC: Navigating the TKI vs ADC Debate

15 days / oncodaily

Stephen V Liu: Intracranial Efficacy of Trastuzumab Deruxtecan in HER2-Mutant NSCLC

15 days / oncodaily

FDA Approves Zongertinib for HER2-Mutated NSCLC – Oncology Brothers

15 days / oncodaily

Zongertinib Receives FDA Accelerated Approval in HER2-Mutant NSCLC

16 days / oncodaily

FDA Voucher Leads to Speedy Approval of Boehringer Drug for First-Line Use in Lung Cancer

18 days / medcitynews / Frank Vinluan

Boehringer wins accelerated approval for first-line use of lung cancer drug

18 days / endpoints / Lei Lei Wu

Saturday, February 28, 2026, 12:23 am / permalink 19927 / 9 stories in 16 days


Novartis to build $23B radioligand therapy site / Beckers

Ella Jeffries / beckershospitalreview - Novartis will construct a 46,000-square-foot radioligand therapy manufacturing site in Denton, Texas, as part of its $23 billion U.S. investment. The facility will be Novartis’ fifth radioligand therapy site in the U.S. and its first in Texas, according t…

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #healthcarefinance

Oklahoma pharmacy school to expand radiopharmaceutical access with new facility

11 days / beckershospitalreview / Ella Jeffries

Novartis to build $23B radioligand therapy site

18 days / beckershospitalreview / Ella Jeffries

Novartis to build another radioligand factory; Germany steps up probe into Gerresheimer

18 days / endpoints / Anna Brown

Saturday, February 28, 2026, 12:23 am / permalink 19926 / 3 stories in 16 days


Patient dies in MacroGenics' cancer study, FDA puts trial on hold / Endpoints

Max Gelman / endpoints - The FDA has placed a partial clinical hold on MacroGenics’ Phase 2 study in gynecologic cancers after one patient died and three others experienced life-threatening side effects, the company disclosed Tuesday. The patient who died ...

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #oncology

Kyowa Kirin ends OX40 trials after Amgen balked, safety concern

13 days / endpoints / Kyle LaHucik

FDA partially pauses cancer drug trial after patient death

19 days / beckershospitalreview / Paige Twenter

Patient dies in MacroGenics' cancer study, FDA puts trial on hold

20 days / endpoints / Max Gelman

Saturday, February 28, 2026, 12:23 am / permalink 19925 / 3 stories in 16 days


Generate Biomedicines’ $400M IPO Puts AI Drug Discovery Back in Focus / OncoDaily

oncodaily - Generate Biomedicines priced its U.S. initial public offering on February 26, 2026, selling 25 million shares at $16 each for gross proceeds of $400 million, with trading expected on the Nasdaq under […]

#healthcare #pharmaceuticals #biotech #drugdevelopment #digitalhealth #healthcarefinance

China obesity biotech QL Biopharm gets $72M, including support from OrbiMed

14 days / endpoints / Kyle LaHucik

Minding the gap – what does China’s biotech boom mean for the UK?

14 days / cancerresearchuk / Tim Bodicoat

Generate Biomedicines’ $400M IPO Puts AI Drug Discovery Back in Focus

16 days / oncodaily

Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug

17 days / medcitynews / Frank Vinluan

Generate:Biomedicines raises $400M IPO, CEO talks about AI's future in drug design

17 days / endpoints / Andrew Dunn

AbbVie budgets $380M for obesity and neuroscience API facilities in Chicago

21 days / endpoints / Anna Brown

Friday, February 27, 2026, 11:22 pm / permalink 19912 / 6 stories in 16 days


Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial / Endpoints

Elizabeth Cairns / endpoints - Novo Nordisk’s GLP-1/amylin combo drug CagriSema was not as good as Eli Lilly’s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday. Patients in the REDEFINE 4 ...

#obesity #healthcare #pharmaceuticals #elililly #novonordisk #weightloss #drugdevelopment

GoodRx Launches Employer Program to Help Subsidize High-Cost Brand Drugs

15 days / medcitynews / Marissa Plescia

GLP-1 news galore; Top 100 venture investors; Doug Ingram to step down; and more

16 days / endpoints / Nicole DeFeudis

Walgreens Introduces Virtual Weight Management Offering

17 days / medcitynews / Marissa Plescia

Walgreens debuts virtual weight management clinic with access to GLP-1 meds

17 days / fiercehealthcare

Understanding GLP-1 signaling: A path to better therapies

17 days / medicalxpress

Novo Nordisk’s ‘strategic conundrum’: How being anchored to the past could cost it the future

17 days / endpoints / Elizabeth Cairns

Walgreens launches $49 virtual weight management visits

18 days / beckershospitalreview / Ella Jeffries

Lilly's GLP-1 pill beats Novo’s in diabetes trial, has more side effects

18 days / endpoints / Elizabeth Cairns

New GLP-1 pill orforglipron outperforms oral semaglutide in yearlong diabetes trial

18 days / medicalxpress

Annie Wong: Transforming Melanoma and Cancer Care Through the 2026 Lea Medal

20 days / oncodaily

Zepbound beats Novo Nordisk’s experimental GLP-1 in head-to-head trial

21 days / beckershospitalreview / Paige Twenter

Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial

21 days / endpoints / Elizabeth Cairns

Thursday, February 26, 2026, 7:23 am / permalink 19788 / 12 stories in 18 days


More Research, Less Cancer: £250m raised to transform the future of cancer research / Cancer Research UK

Charlotte Mathé / cancerresearchuk - We’ve reached an incredible moment - £250m raised for our More Research, Less Cancer campaign. This milestone brings us more than halfway to our £400m goal and accelerates our mission to prevent, detect and treat cancer earlier and more effectively. The p…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #oncology

Top OncoGrants of the Week: Pilot Funding, Team Science, Clinical Trials, and Survivorship Awards (2026)

15 days / oncodaily

COLONTOWN Expands Patient Support With New Online Space for Colorectal Cancer Care

15 days / oncodaily

Why Hasn’t Immunotherapy Consistently Delivered in HER2+ Disease? – The Breast Friends

18 days / oncodaily

Susanna Fletcher Greer: Breaking Walls and Building Remission for Lymphoma Patients

18 days / oncodaily

Transforming Geriatric Oncology Together at Treviso 2026 – SIOG

18 days / oncodaily

Nabil Ismaili: Recent Data are Shifting the Historical Paradigm

18 days / oncodaily

Melvin LK Chua: New Podcast Episode With The Deep Margin

18 days / oncodaily

Charles Roberts Celebrates the Researchers Shaping the Future of Cancer Science

18 days / oncodaily

Laser heat therapy plus immunotherapy may dramatically improve survival for those with deadly brain cancer

18 days / medicalxpress

Gonzalo López-Cuevas: Alcohol, Cancer and the Case for Stronger Public Policy in Mexico

18 days / oncodaily

Final Phase 3 CONVERT Trial Results: Neoadjuvant CAPOX vs Capecitabine-Based ChemoRT in Locally Advanced Rectal Cancer

18 days / oncodaily

Screening Programme by Primary Colonoscopy or Two Rounds of Two-Stool FIT Detects More Lower-Stage CRCs than Usual Care

18 days / esmo

Joanna Sadowska: Pfizer Gets FDA Approval for BRAFTOVI as First-Line Treatment for Metastatic Colorectal Cancer

18 days / oncodaily

Exploring Extracellular Vesicle-Mediated Communication in Early PDAC – Pancreatic Cancer Europe

19 days / oncodaily

Good vibrations: could sound waves help diagnose prostate cancer?

19 days / cancerresearchuk / Tim Gunn

Tumor genomics in patients younger than 40 years of age with metastatic breast cancer

19 days / nature

Dato’ Dr Saunthari Somasundaram: Closer to a Future Without Cervical Cancer

19 days / oncodaily

Wing F. Li: Our Latest Review on TP53-Mutated AML/MDS

19 days / oncodaily

Myeloma Paper of the Day, February 25th, Suggested by Robert Orlowski

19 days / oncodaily

Ola Amareen: Digital Solutions for Mental Health in Cancer Care

19 days / oncodaily

Neurosurgeons are really good at removing brain tumors—they're about to get even better

19 days / medicalxpress

Timothy Rebbeck: The Future of Early Detection with Liquid Biopsy

19 days / oncodaily

Douglas Flora: The Mathematics of Compassion

19 days / oncodaily

Flavio Rocha: Cancer Is a Full-Time Job, But Sometimes It’s Personal

19 days / oncodaily

Sendurai Mani: New “Hallmarks of Cancer” Virtual Seminar Series

19 days / oncodaily

Martha Wanjiru: HPV Screening and Vaccination as Pillars of Community Health

19 days / oncodaily

Al-Ola Abdallah: Teamwork Never Takes a Day Off

19 days / oncodaily

Kunal Sharma։ The Role of Digital Pathology and Artificial Intelligence in Today’s Era

19 days / oncodaily

Congratulations to Brian Wolpin and Andrew Aguirre on the 2026 Early Detection Award – Dana-Farber Cancer Institute

19 days / oncodaily

Giselle Sholler: THON 2026 Raised $18.8M for Children with Cancer

19 days / oncodaily

Teresa Amaral: Europe’s Clinical Trial Landscape and the Path to Global Competitiveness

19 days / oncodaily

Showcase your science and win!

19 days / cancerresearchuk / Cancer Research UK

Epigenetic reactivation of the tumor suppressor ZBTB7A by KDM4 inhibition in human acute myeloid leukemia

19 days / science / Alexander Arnuk, Cuijuan Han, Abimbola E. Lawal, Bofei Wang, Sadik Karma, Zhiping Zhang, Mhd Yousuf

Cervical cancer rates plummet among states with high HPV vaccination rates

20 days / medicalxpress

Make 2026 a turning point for cancer in Scotland and Wales

20 days / cancerresearchuk / Tim Gunn

Cancer-Associated fibroblasts regulate the development of cholangiocarcinoma through IL-6/STAT3/AKR1C3 signaling axis

20 days / nature

Myeloma Paper of the Day, February 24th, Suggested by Robert Orlowski

20 days / oncodaily

ECHoS calls for a bold move to Accelerate Europe’s Fight Against Cancer in the next Framework Programme (FP10)

20 days / oncodaily

10 Oncology Specialists Join OncoDaily Medical Journal’s Editorial Team

20 days / oncodaily

$100 Million Raised by Dolphins Cancer Challenge for Cancer Research and Care

20 days / oncodaily

Mauro A. Ferreira: Proton Therapy and the Future of Pediatric Cancer Care in Brazil

20 days / oncodaily

Tracey O’Brien: Proud to Partner with Multicultural Communities to Share Life-Saving Cancer Messages

20 days / oncodaily

Sara Zanivan: Welcoming New Postdocs at MD Anderson Cancer Center

20 days / oncodaily

Laura Valle: Germline and Tumor Sequencing for Hereditary Cancer Care

20 days / oncodaily

New strategy grabs cancer's 'undruggable' proteins and throws them in the cellular trash

20 days / medicalxpress

Sepideh Gholami: AACR/ASCO Workshop Trains the Next Generation of Cancer Researchers

20 days / oncodaily

Amin Firoozmand: Research Summit Strengthens Collaboration to Expand Clinical Trial Access in Hematologic Malignancies

20 days / oncodaily

Michele Matta: Cancer Prevention Europe Launches First Career Development Webinar

20 days / oncodaily

Nabil Ismaili: 2025 Strategy for HR+/HER2- Breast Cancer Embraces Dynamic ctDNA Monitoring

20 days / oncodaily

Nick Grant: £250m Raised for the More Research Less Cancer Campaign

20 days / oncodaily

£250m Raised to Transform the Future of Cancer Research – Cancer Research UK

20 days / oncodaily

More Research, Less Cancer: £250m raised to transform the future of cancer research

21 days / cancerresearchuk / Charlotte Mathé

Woman's regret over botched Brazilian butt lift

21 days / bbc

Tuesday, February 24, 2026, 1:24 pm / permalink 19675 / 53 stories in 20 days


FDA Launches Framework to Accelerate Individualized Therapies for Ultra-Rare Diseases 2026 / OncoDaily

oncodaily - The U.S. Food and Drug Administration (FDA) has released groundbreaking draft guidance introducing a new regulatory framework designed to accelerate the development and approval of individualized therapies for patients with […]

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda

Senate hearing raises FDA-related concerns for new rare disease drugs

18 days / endpoints / Zachary Brennan

Ugur Sahin: Individualized mRNA Vaccines Evoke Durable T Cell Immunity in Adjuvant TNBC

19 days / oncodaily

Trish Brown: Had the pleasure of attending the FDA announcement at HHS with Linda Genen

20 days / oncodaily

FDA Launches Framework to Accelerate Individualized Therapies for Ultra-Rare Diseases 2026

20 days / oncodaily

FDA unveils pathway for ultra-rare disease therapies

21 days / beckershospitalreview / Ella Jeffries

FDA unveils long-awaited guidance on new pathway for individualized therapies

21 days / endpoints / Zachary Brennan

Tuesday, February 24, 2026, 12:25 pm / permalink 19669 / 6 stories in 20 days


Gilead to acquire cell therapy manufacturer for $7.8B / Beckers

Paige Twenter / beckershospitalreview - In a deal worth $7.8 billion, Gilead Sciences has entered a definitive agreement to acquire Arcellx, a biotech company developing a cell therapy for multiple myeloma. Gilead announced the acquisition agreement a few months after Arcellx published positive…

#healthcare #pharmaceuticals #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #fda #oncology

Vir–Astellas Prostate Cancer Deal and ALX Oncology’s 2025 Results Set 2026 Catalysts

16 days / oncodaily

Gilead–Arcellx Deal: Up to $7.8B for Anito-cel CAR-T in Multiple Myeloma

18 days / oncodaily

'Off the shelf' immunotherapy could get a lift from gene-edited natural killer cells

19 days / medicalxpress

Megan Melody on CAR T-Cell Therapy Advances in Autoimmune Disease

19 days / oncodaily

Gilead to acquire cell therapy manufacturer for $7.8B

21 days / beckershospitalreview / Paige Twenter

Gilead Sciences Is Acquiring Arcellx and Partnered Multiple Myeloma Drug in $7.8B Deal

21 days / medcitynews / Frank Vinluan

Gilead to acquire cell therapy partner Arcellx for $7.8B

21 days / endpoints / Lei Lei Wu

Monday, February 23, 2026, 4:23 pm / permalink 19605 / 7 stories in 21 days


Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin / ESMO

esmo - Findings from the KEYNOTE-905/EV-303 study

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology

Blood test predicts which bladder cancer patients may safely skip surgery

17 days / medicalxpress

Perioperative enfortumab vedotin + pembrolizumab tied to improved outcomes with bladder cancer

17 days / medicalxpress

Padcev-Keytruda combo delivers more positive data in bladder cancer

17 days / endpoints / Max Gelman

Neeraj Agarwal on ASCO GU 2026: Survival Signals, Biomarkers and the Future of GU Trials Part 2

17 days / oncodaily

Javier Molina Cerrillo: Liver Metastases in Advanced UC – Does Immunotherapy Make a Difference?

19 days / oncodaily

Shilpa Gupta: Latest Advances in Bladder Cancer at ASCO GU 2026

19 days / oncodaily

10 Must-Read Posts in Immuno-Oncology This Week

20 days / oncodaily

ASCO GU 2026: 10 Most Promising Trials Shaping the Future of Genitourinary Oncology

20 days / oncodaily

Ahmet Dirican: MIBC Staging Is No Longer Just Anatomical

20 days / oncodaily

Muharrem Coşkunpınar: Expanding Perspectives in Metastatic Bladder and Kidney Cancer Care

20 days / oncodaily

Recipients of the Conquer Cancer 2026 Genitourinary Cancers Symposium Merit Awards

21 days / oncodaily

Andrea Necchi: Multidisciplinary Effoert Needed for Treating Variant Histologies of Bladder Cancer

21 days / oncodaily

Shilpa Gupta: Grateful to ASCO For the Opportunity to Serve as ASCOGU26 Featured Voice

21 days / oncodaily

Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin

21 days / esmo

Jad Chahoud Celebrates Nabil Adra Advancing Pembrolizumab-EV in Bladder Cancer

24 days / oncodaily

Monday, February 23, 2026, 2:22 am / permalink 19558 / 15 stories in 21 days


Data and Decisions in Advanced NSCLC at the 2026 TTLC Symposia – IASLC / OncoDaily

oncodaily - International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn: “2026 TTLC Symposia Event Data and Decisions in Advanced NSCLC The treatment landscape for advanced NSCLC is evolving […]

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology

Christine M. Lovly։ Dr. Ross Camidge’s Incredible Presentation at the IASLC TTLC Meeting

17 days / oncodaily

Rishabh Jain: Antibiotics, Microbiome and Immunotherapy Outcomes in Lung Cancer

17 days / oncodaily

Dual Immunotherapy and the Microbiome Signal – Lung Cancer Europe

17 days / oncodaily

This Report Provides a Clear View of Where We Stand in Addressing Cancer – LUNGevity Foundation

18 days / oncodaily

Updated Oncogene-Addicted mNSCLC Living Guideline v1.3

18 days / esmo

Narjust Florez: Meaningful Connections at the 2026 Targeted Therapies of Lung Cancer Meeting

19 days / oncodaily

Ahmet Dirican: Real-World Data Discontinuation of Immunotherapy at 24 months in Metastatic NSCLC

19 days / oncodaily

Chinmay Jani Discusses Real-World Impact of Subcutaneous Amivantamab at TTLC 2026

19 days / oncodaily

Simon Heeke: Innovative Approaches for Lung Cancer Screening and Interception

19 days / oncodaily

Editors’ Picks, February 2026: FDA’s Accelerated Approval Pathway, Overcoming Resistance to KRAS Inhibition, and More

19 days / aacr / Cancer Research Catalyst Staff

When Promising Results Demand Rigorous Scrutiny: Lessons from the LungTIME-C01 Trial

19 days / oncodaily

Vandana Mahajan: 169th Lung Connect Meeting Showcases the Role of Clinical Trials

20 days / oncodaily

Yvonne Diaz: IASLC Programs Open Opportunities for Lung Cancer Advocates in Research

20 days / oncodaily

Eric Singhi: Innovative Approaches for Lung Cancer Screening and Interception

20 days / oncodaily

Rajat Thawani: Talking About NGR1 Fusions in NSCLC at TTLC26

20 days / oncodaily

Mamtha Balla: ITE Boards Pearls for Metastatic NSCLC

21 days / oncodaily

Giannis Mountzios: ESMO Advanced Course on Early-Stage NSCLC

21 days / oncodaily

Gavitt Woodard: Great Time at TTLCC26 With Yale Thoracic Group

21 days / oncodaily

Fawzi Abu Rous: Inspiration, Insights and Impact from TTLC 2026

22 days / oncodaily

Data and Decisions in Advanced NSCLC at the 2026 TTLC Symposia – IASLC

23 days / oncodaily

Fawzi Abu Rous Kicks Off Season 2 of LungCancerRx LIVE at TTLC 2026

24 days / oncodaily

Fawzi Abu Rous: Integrating the Latest Evidence Into the Treatment of EGFR-mutated NSCLC

24 days / oncodaily

Study finds immune signature linked to treatment-resistant myasthenia gravis

24 days / medicalxpress

Monday, February 23, 2026, 2:22 am / permalink 19557 / 23 stories in 21 days


A novel C. diff vaccine shows promise / Beckers

Mariah Taylor / beckershospitalreview - Nashville, Tenn.-based Vanderbilt Health researchers have developed a promising novel vaccine to treat Clostridioides difficile infections. Previous vaccine strategies targeted the bacterium’s primary toxins, according to a Feb. 18 system news release. Th…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #vaccinesafety

A novel C. diff vaccine shows promise

25 days / beckershospitalreview / Mariah Taylor

Experimental vaccine protects against C. diff disease and recurrence

26 days / medicalxpress

Saturday, February 21, 2026, 7:21 am / permalink 19520 / 2 stories in 23 days


Back to Top


PHARMACEUTICALS Heatmap

90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.



More Top Stories...

FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...


FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...


CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...


Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...


City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...


NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.